The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. CTAF convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the CTAF process, and find out how topics are selected.
CTAF directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the CTAF Panel must meet ICER’s criteria for Conflict of Interest.
For an archive of CTAF reports published prior to September 2013, please visit this page.
The box below provides information on the topic of the next meeting of CTAF. For more information about past and other upcoming meetings, see the box to the right.
Next Meeting
The California Endowment Los Angeles Conference Center
1000 N. Alameda St.
Los Angeles, CA, 90012
Osteoporosis
The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.
Register or Register for the Live WebcastOsteoporosis
Osteoporosis, the weakening of the bones through loss of bone mineral content and a decrease in bone quality, is a common disease of aging that affects approximately 10 million Americans. Approximately half of women and one quarter of men will suffer at least one fracture due to osteoporosis during their lifetimes. Experts estimate that there are approximately two million osteoporotic fractures each year, which results in $19 billion in related costs. By 2025, these figures are predicted to grow to approximately three million fractures and $25 billion in costs annually as the population of older Americans increases.
Interventions of Interest:
- Abaloparatide (Radius Health, Inc.)
- Romosozumab (Amgen, Inc. and UCB, Inc.)
- Teriparatide (Forteo®, Eli Lilly and Co.)
